Amgen and FTC reach settlement allowing $27.8 billion acquisition of Horizon Therapeutics to proceed

The FTC initially sued to block the deal over competition concerns but has now reached a settlement with Amgen.
Under the settlement, Amgen cannot bundle its products with two of Horizon's key drugs.
Amgen must seek FTC approval before acquiring products that treat the same diseases as those two Horizon drugs.
The deal is expected to close in the fourth quarter of 2022 after the states' lawsuits are dismissed.
The settlement aims to ensure fair competition in the pharmaceutical industry.